TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25938628
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment
Study: 11340797
Drug: Specific speech
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific speech and language therapy (SLT) including a portable metronome brooch to cue swallowing
Study: 11340797
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of botulinum toxin into both parotid glands
Study: 10660242
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 3 microg/kg
Study: 7715908
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous IL-2 (3 million IU/day for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally)
Study: 339662
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg daily during three consecutive days, every fortnight)
Study: 31496316
Drug: Periulcer foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periulcer foam sclerotherapy injection using Aethoxysklerol 1%
Study: 31496316
Drug: Periulcer foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periulcer foam sclerotherapy injection
Study: 25994074
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion (2 pmol kg(‐1) min(‐1))
Study: 25994074
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion with hyperinsulinaemic-euglycaemic (EU) clamp
Study: 25994074
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion with hyperinsulinaemic-hyperglycaemic (HC) clamp
Study: 25994074
Drug: Sole GIP
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole GIP infusion
Study: 3197373
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (154 mmol/l NaCl)
Study: 25994074
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion with hyperinsulinaemic-euglycaemic (EU) clamp
Study: 25994074
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion with hyperinsulinaemic-hyperglycaemic (HC) clamp
Study: 25994074
Drug: Sole placebo
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole placebo infusion
Study: 18979143
Drug: Nizatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (150 mg bd)
Study: 9294990
Drug: Pravastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin + Gemfibrozil (20 mg + 1200 mg/day)
Study: 9294990
Drug: Simvastatin +
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin + Gemfibrozil (20 mg + 1200 mg/day)
Study: 9294990
Drug: Simvastatin +
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin + Ciprofibrate (20 mg + 100 mg/day)
Study: 9294990
Drug: All combination
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All combination treatments
Study: 20399985
Drug: Ziprasidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (20 and 30 mg)
Study: 20399985
Drug: Haloperidol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (7.5 and 10 mg)
Study: 12882611
Drug: Phonophoresis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis of ketoprofen gel using continuous ultrasound (1 MHz, 1.5 W/cm2, for 5 minutes)
Study: 12882611
Drug: Phonophoresis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis of ketoprofen gel using pulsed ultrasound (100 Hz, 20% duty cycle)
Study: 8895048
Drug: Alpha-glucosidase inhibitor
Normalized name: Alpha-glucosidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-glucosidase inhibitor replacing part of insulin in Group 2 (n = 10)
Study: 1900686
Drug: Induced Hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced Hypertension Chemotherapy (IHC) using angiotensin II human (TY-10721) with adriamycin (33 mg/m2, day 3), 5-fluorouracil (330 mg/m2/day through day 1 to 3, 8 to 10), and mitomycin C (5 mg/m2, day 8), repeated every 4 weeks.
Study: 26768436
Drug: gabapentin +
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gabapentin + dexamethasone + 5HT3 receptor antagonist
Study: 1535579
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg
Study: 16200718
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + micronized progesterone (100 mg/d) in group 1 (G1)
Study: 16200718
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + medroxyprogesterone acetate (2 mg/d) in group 2 (G2)
Study: 9029746
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered immediately after pholcodine (25 g)
Study: 9029746
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered 2 hours after pholcodine (25 g)
Study: 9029746
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of activated charcoal (10 g every 12 h for 84 h)
Study: 9029746
Drug: Pholcodine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pholcodine administered on an empty stomach with water only (100 mg)
Study: 3310941
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of administered norfloxacin twice daily for three days
Study: 3310941
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days
Study: 18467316
Drug: Induction chemoradiotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemoradiotherapy (CHRT) with 60 Gy, infusional 5-FU (300 mg/m²/day for 6 weeks), and intermittent cisplatin (20 mg/m²/day during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m² weekly for 3/4 weeks)
Study: 12865191
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (oestradiol valerate and medroxyprogesterone acetate)
Study: 8880021
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg acetylsalicylic acid
Study: 25025755
Drug: Nilotinib 300
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg BID
Study: 25025755
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg BID
Study: 21682350
Drug: DRV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r monotherapy (800/100 mg once daily)
Study: 20010070
Drug: DRV/r with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r with two nucleoside reverse transcriptase inhibitors (NRTIs)
Study: 17346436
Drug: PMBL sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMBL sublingual treatment
Study: 14582440
Drug: Trimetazidine and
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine and perindopril (combined treatment)
Study: 30053212
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 1000 mg × 2 doses at 0, 15 days
Study: 30053212
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYC) 500 mg/m2 monthly
Study: 12839279
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zinc daily for 5 days a week for 16 weeks
Study: 6476319
Drug: Atropine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.6 mg intravenously
Study: 9884857
Drug: Glycopyrrolate 0.2
Normalized name: glycopyrrolate 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.2 mg intravenously
Study: 21109132
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (1.5 mg/kg propofol)
Study: 21109132
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (2 mg/kg propofol)
Study: 8594696
Drug: DEC 6
Normalized name: Zodryl DEC 60 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 6 mg/kg alone
Study: 8594696
Drug: IVR 400
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR 400 micrograms/kg plus DEC 3 mg/kg
Study: 2706316
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sustained-release methylphenidate (SR)
Study: 2706316
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg immediate-release methylphenidate (IR)
Study: 2706316
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of SR formulations
Study: 770081
Drug: Azapropazone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone 1200 mg per day
Study: 31837624
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy (CBGT)
Study: 19346279
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg)
Study: 28063907
Drug: Standard curriculum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard curriculum plus weekly video coaching by an expert laparoscopic surgeon
Study: 19196468
Drug: Oral dihydrocodeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dihydrocodeine
Study: 16538135
Drug: Rewetting drops
Normalized name: Opti-Free Rewetting Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rewetting drops (carboxymethylcellulose 0.5%, Refresh Contacts) twice per day
Study: 12545629
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of 2% lidocaine gel in the endorectal (group 1)
Study: 12545629
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of 1% lidocaine solution injected into the apex (group 2)
Study: 9798805
Drug: L plus
Normalized name: Ionil Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L plus clarithromycin (C) 250 mg b.d. plus tinidazole (T) 500 mg b.d. for 7 days (LCT)
Study: 9798805
Drug: RBC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC plus C 250 mg b.d. and T 500 mg b.d. for 7 days (RbcCT)
Study: 7617820
Drug: 50 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/70 kg intravenous diphenhydramine
Study: 23237788
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (1600 mg EGCG and 600 mg caffeine)
Study: 10495984
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/day
Study: 27712774
Drug: No CTO
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CTO PCI (conservative treatment without PCI of the CTO)
Study: 20458045
Drug: Intense dose-dense
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide (IDD-ETC) every 2 weeks
Study: 20458045
Drug: Conventionally scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally scheduled chemotherapy with epirubicin/cyclophosphamide followed by paclitaxel every three weeks
Study: 12589345
Drug: Omalizumab (≥0.016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (≥0.016 mg/kg of IgE per 4 weeks)
Study: 6440740
Drug: Levonorgestrel 20
Normalized name: ethinyl estradiol-levonorgestrel 20 mcg-90 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 20 mcg/day device
Study: 19020749
Drug: Cetuximab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (single agent)
Study: 29274893
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment (SBT)
Study: 29274893
Drug: Acceptance-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based treatment (ABT)
Study: 30071866
Drug: Implementation success
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation success measures (e.g., # of peer groups held)
Study: 17664952
Drug: Methotrexate plus
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate plus intramuscular gold
Study: 17664952
Drug: Triple DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple DMARD therapy
Study: 11666125
Drug: TTFCA 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 60 mg thrice daily (Group A)
Study: 11666125
Drug: TTFCA 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 30 mg thrice daily (Group B)
Study: 8305420
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) plus 10 mg medroxyprogesterone acetate (MPA)
Study: 8305420
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE only
Study: 20418523
Drug: BoNT‐A (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A (500 U Dysport) injection
Study: 15325934
Drug: Edaravone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone administration before myocardial reperfusion
Study: 8058353
Drug: Baclofen administration
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen administration (10 subjects)
Study: 808194
Drug: Isotonic 5
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic 5 percent crystalline amino acid solution
Study: 2103529
Drug: Topical levobunolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobunolol treatment for four months
Study: 22291112
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime for 10 days
Study: 22291112
Drug: Sequential intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous ceftriaxone for 4 days followed by oral cefixime for 6 days
Study: 15821197
Drug: AM3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM3 (3 g/d for 180 days)
Study: 388401
Drug: tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tienilic acid (mean dose 210 mg)
Study: 21118395
Drug: Omeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (10 mg once daily) plus mosapride citrate (5 mg three times a day)
Study: 19391529
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point taping and pressing therapy
Study: 12383535
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 microg) orally every hour for a maximum of three doses
Study: 12383535
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally every hour for a maximum of three doses
Study: 9819040
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at 70 microg/kg dosage
Study: 9819040
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at 35 microg/kg dosage
Study: 7699549
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of nebulized ipratropium bromide (250 micrograms/dose)
Study: 7699549
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of nebulized ipratropium bromide
Study: 2539929
Drug: Eicosapentanoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentanoic acid (EPA) 10 g per day
Study: 25369200
Drug: 600 µg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 µg of misoprostol sublingually
Study: 21953471
Drug: Ibandronate 100
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 100 mg monthly
Study: 25856225
Drug: Ibandronate 150
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150 mg monthly
Study: 21953471
Drug: Ibandronate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (100 mg and 150 mg monthly)
Study: 7867679
Drug: Acrivastine 16
Normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acrivastine 16 mg
Study: 1970907
Drug: Acrivastine 8
Normalized name: acrivastine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine 8 mg
Study: 10664928
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg and 20 mg
Study: 7888428
Drug: Ademetionin (therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ademetionin (therapy group)
Study: 29875218
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (DMF) in treatment-naive patients
Study: 7892014
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 30 mg
Study: 7892014
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 45 mg
Study: 7892014
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 15 mg
Study: 12728166
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray
Study: 2831814
Drug: Once-daily use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily use of interferon
Study: 22725836
Drug: Curcuminoid/piperine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoid/piperine treatment (4 g curcuminoids plus 24 mg piperine)
Study: 20957329
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (problem-solving)
Study: 16864148
Drug: E2/NETA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (2 mg E2 plus 1 mg NETA)
Study: 7650224
Drug: 40-mg famotidine
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg famotidine wafer
Study: 7650224
Drug: 20-mg and
Normalized name: zinc pyrithione 20 MG/ML [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg and 40-mg famotidine wafers
Study: 29371008
Drug: School-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based program promoting outdoor activities (up to 11 hours weekly)
Study: 22020318
Drug: Vorinostat 800
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 800 mg/day
Study: 22020318
Drug: Vorinostat 1400
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 1400 mg/day
Study: 16712781
Drug: schema focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: schema focused therapy or transference focused psychotherapy
Study: 19422627
Drug: Alcohol (0.82
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.82 g/kg)
Study: 11956511
Drug: Indinavir (C(max)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (C(max) > 7 microg/ml)
Study: 11956511
Drug: Indinavir (C(max)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (C(max) < 7 microg/ml)
Study: 9822864
Drug: Greater than
Normalized name: immune globulin,alpha (IgA) greater than 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater than normal expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) (57.1 +/- 2.3)
Study: 31601466
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow nucleated cell (BMNc) injection
Study: 28619050
Drug: Brief Admission
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Admission Skåne plus Treatment as Usual
Study: 15674006
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20 minutes, twice weekly, for 12 weeks)
Study: 15674006
Drug: Friendly visit
Normalized name: Fisherman's Friend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friendly visit (control group, reading, talking, playing quiet games, twice weekly for 12 weeks)
Study: 8077977
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (morphine)
Study: 26098847
Drug: ARB (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (40 mg/day olmesartan) for eight weeks
Study: 17717237
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine 1.5 mg
Study: 16243989
Drug: IV ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ondansetron 4 mg
Study: 29415730
Drug: Pre‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐ and postnatal small‐quantity lipid‐based nutrient supplements for both mother and child
Study: 27464984
Drug: IPE-27 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPE-27 (10 g/day)